In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Anti-TIGITs Prove Their Value in 2023?

Executive Summary

The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline. 

You may also be interested in...



Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails

Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.

Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss

Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.

Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV146785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel